Sale!

Anastrozole (0.5mg/capsule), 60 Capsules

Original price was: $79.95.Current price is: $64.03.

699 in stock

Free shipping on all orders over $100 (US) and $300 (International)

• 7-Days Return Policy

Guaranteed Safe Checkout:

Anastrozole (0.5mg/capsule), 60 Capsules 1

Description

Anastrozole is classified as a non-steroidal aromatase inhibitor that acts by preventing the conversion of androgens to estrogens. It is being researched to reduce estrogen levels that circulate in the body and as a breast cancer prevention therapy.

Description

Anastrozole is classified as a non-steroidal aromatase inhibitor that acts by preventing the conversion of androgens to estrogens. It is being researched to reduce estrogen levels that circulate in the body and as a breast cancer prevention therapy.

Properties

  • Chemical Formula :C17H19N5
  • Synonyms :120511-73-1, Arimidex, Anastrazole, Anastrozol
  • Molar Mass :293.4 g/mol
  • CAS Number :120511-73-1
  • PubChem :44256128
  • Total Amount of the Active Ingredient :30mg (0.5mg per capsule)
  • Shelf Life :36 months

Anastrozole is classified as a non-steroidal aromatase inhibitor that acts by preventing the conversion of androgens to estrogens. It is being researched to reduce estrogen levels that circulate in the body and as a breast cancer prevention therapy.

  • Chemical Formula :C17H19N5
  • Synonyms :120511-73-1, Arimidex, Anastrazole, Anastrozol
  • Molar Mass :293.4 g/mol
  • CAS Number :120511-73-1
  • PubChem :44256128
  • Total Amount of the Active Ingredient :30mg (0.5mg per capsule)
  • Shelf Life :36 months
Anastrozole

Product Quality Guaranteed

All of our products are lab tested and the results are occasionally published on the website.

You can have the product you bought from us tested at any HPLC-licensed testing facility and if the results are negative, we will refund the following:

  • Cost of HPLC test
  • Total amount of the order + shipping fee

Peer-Reviewed Studies

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

Bonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., ... & Von Euler, M. (2000).

Journal of Clinical Oncology, 18(22), 3748-3757.

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

Cuzick, J. (2008).

Expert review of anticancer therapy, 8(9), 1377-1385.

Other Products Explore All

Explore All